Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 23 Dec 2022

Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

in Cancer Molecular Targets and Therapeutics

Yezhe Cheng
Xiaoxi Yuan
Qiang Tian
Xiuying Huang
Yang Chen
Yuzhi Pu
Hu Long
Mingyu Xu
Yafei Ji
Jia Xie

Frontiers in Oncology

doi 10.3389/fonc.2022.951589

35,849 views
42 citations

Brief Research Report

Published on 23 Dec 2022

Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study

in Cancer Molecular Targets and Therapeutics

Darshana Patil
Dadasaheb Akolkar
Rajnish Nagarkar
Navin Srivastava
Vineet Datta
Sanket Patil
Sachin Apurwa
Ajay Srinivasan
Rajan Datar

Frontiers in Oncology

doi 10.3389/fonc.2022.972322

2,474 views
4 citations

Review

Published on 22 Dec 2022

LINC00324 in cancer: Regulatory and therapeutic implications

in Cancer Molecular Targets and Therapeutics

Qing Xia
Jinze Shen
Qurui Wang
Yufei Ke
Qibin Yan
Hanbing Li
Dayong Zhang
Shiwei Duan

Frontiers in Oncology

doi 10.3389/fonc.2022.1039366

2,497 views
9 citations

Review

Published on 22 Dec 2022

The role and mechanism of claudins in cancer

in Cancer Molecular Targets and Therapeutics

De-Wen Wang
Wei-Han Zhang
Galiullin Danil
Kun Yang
Jian-Kun Hu

Frontiers in Oncology

doi 10.3389/fonc.2022.1051497

10,207 views
43 citations

Case Report

Published on 22 Dec 2022

Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma

in Cancer Molecular Targets and Therapeutics

Xiangming Fang
Haibo Mou
Xinxin Ying
Xuehua Hou
Luo Wang
Ying Wu
Naimeng Yan
Lijie Guo
Qin Liao

Frontiers in Oncology

doi 10.3389/fonc.2022.1024677

2,077 views
3 citations

Original Research

Published on 19 Dec 2022

Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma

in Cancer Molecular Targets and Therapeutics

Jie Wei
Jianfeng Wu
Zhiyong Yin
Xia Li
Yixiong Liu
Yingmei Wang
Zhe Wang
Chao Xu
Linni Fan

Frontiers in Oncology

doi 10.3389/fonc.2022.1048482

1,897 views
4 citations

Review

Published on 16 Dec 2022

The role of IL-6/JAK2/STAT3 signaling pathway in cancers

in Cancer Molecular Targets and Therapeutics

Bei Huang
Xiaoling Lang
Xihong Li

Frontiers in Oncology

doi 10.3389/fonc.2022.1023177

28,723 views
228 citations

Review

Published on 16 Dec 2022

The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance

in Cancer Molecular Targets and Therapeutics

Mara Zippoli
Anna Ruocco
Rubina Novelli
Francesca Rocchio
Martina Sara Miscione
Marcello Allegretti
Maria Candida Cesta
Pier Giorgio Amendola

Frontiers in Oncology

doi 10.3389/fonc.2022.947183

4,878 views
3 citations

Original Research

Published on 14 Dec 2022

Gou Qi Zi inhibits proliferation and induces apoptosis through the PI3K/AKT1 signaling pathway in non-small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Lingling Zhang
Yanju Gong
Lei Zhang
Bing Liang
Huan Xu
Wangming Hu
Zhong Jin
Xiao Wu
Xiongbin Chen
Min Li

Frontiers in Oncology

doi 10.3389/fonc.2022.1034750

3,968 views
6 citations

Original Research

Published on 14 Dec 2022

Knowledge mapping of alternative splicing of cancer from 2012 to 2021: A bibliometric analysis

in Cancer Molecular Targets and Therapeutics

Bo Tian
Yan Bian
De-Jian Bian
Ye Gao
Xun Zhang
Si-Wei Zhou
Yan-Hui Zhang
Ya-Nan Pang
Zhao-Shen Li
Luo-Wei Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.1068805

4,715 views
3 citations

Original Research

Published on 14 Dec 2022

Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA

in Cancer Molecular Targets and Therapeutics

Yingwei Wang
Qixin Wang
Zan Chen
Jian Yang
Hanxiang Liu
Dengsai Peng
Lei Lei
Lin Liu
Li Wang
Naiguo Xing

Frontiers in Oncology

doi 10.3389/fonc.2022.1027792

2,615 views
23 citations

Original Research

Published on 14 Dec 2022

Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models

in Cancer Molecular Targets and Therapeutics

Dengxu Tan
Jiaze An
Miaomiao Gong
Huihui Wang
Han Li
Han Meng
Caiqin Zhang
Yong Zhao
Xu Ge
Changhong Shi

Frontiers in Oncology

doi 10.3389/fonc.2022.1043479

3,486 views
9 citations

Review

Published on 13 Dec 2022

Targeted therapy of RET fusion-positive non-small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Zixiong Shen
Binxu Qiu
Lin Li
Bo Yang
Guanghu Li

Frontiers in Oncology

doi 10.3389/fonc.2022.1033484

11,636 views
16 citations

Correction

Published on 13 Dec 2022

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

in Cancer Molecular Targets and Therapeutics

Sha-Sha Wang
Fang Wang
Zhen Zeng
Fang Gao
Huan-Huan Liu
Hui-Na Wang
Yi Hu
Hai-Feng Qin

Frontiers in Oncology

doi 10.3389/fonc.2022.1113289

933 views

Case Report

Published on 12 Dec 2022

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

in Cancer Molecular Targets and Therapeutics

Margherita Nannini
Andrea Repaci
Gianluca Ricco
Manuela Ianni
Arber Golemi
Vincenzo Maiolo
Marco Ferrari
Filippo Natali
Elisa Lodi Rizzini
Fabio Monari

Frontiers in Oncology

doi 10.3389/fonc.2022.1042525

2,199 views
2 citations

Case Report

Published on 12 Dec 2022

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report

in Cancer Molecular Targets and Therapeutics

Veronika Blum
Vanghelita Andrei
Baptiste Ameline
Silvia Hofer
Bruno Fuchs
Klaus Strobel
Anna Allemann
Beata Bode
Daniel Baumhoer

Frontiers in Oncology

doi 10.3389/fonc.2022.1086677

3,874 views
5 citations